Fig. 10

Pharmacokinetic profiles of free EPI and EPI/Por-PCL-PH-PEG-cRGD nanoparticles (a). In vivo antitumor efficiency of EPI/Por-PCL-PH-PEG-cRGD, EPI/Por-PCL-PH-PEG-cRGD + laser, free EPI, laser and saline (as control). The volume of tumors (b); body weights (c). The EPI dosage was 5 mg/kg and p values were calculated at 30 days (*P < 0.05; **P < 0.01; ***P < 0.001); d In vivo imaging studies of DiD/Por-PCL-PH-PEG-cRGD nanoparticles, DiD/PEG-PCL nanoparticles and free DiD at 0.5 h, 2 h, 8 h, and 24 h after injection